Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- American Academy of Dermatology. Indoor tanning. Available at https://www.aad.org/media/stats/prevention-and-care
- Bareford D, Cumberbatch M, Derrick Tovey L. 1984. Plasma discolouration due to sun-tanning aids. Vox Sanguinis, 46(3):180-182.
- Beaulieu RA, et al. 2013. Canthaxanthin retinopathy with visual loss: A case report and review. Case Rep Ophthalmol Med, Article ID 40901.
- European Commission. 2010. Scientific Committee on Consumer Safety. Opinion on dihydroxyacetone. Available at https://ec.europa.eu/health/sites/default/files/scientific_committees/consumer_safety/docs/sccs_o_048.pdf
- Lapunzina P. 1996. Ultraviolet light-related neural tube defects? Am J Med Genet, 67:106.
- Meadows M. 2003. Don't be in the dark about tanning. FDA Consumer Magazine, 37:6.
- United States Food and Drug Administration. 2018. Sunless tanners and bronzers. Available at https://www.fda.gov/Cosmetics/ProductsIngredients/Products/ucm134064.htm
- United States Food and Drug Administration. 2005. Tanning Pills. Available at https://www.fda.gov/cosmetics/cosmetic-products/tanning-pills
- Yourick JJ, et al. 2004. Fate of chemicals in skin after dermal application: Does the in vitro skin reservoir affect the estimate of systemic absorption? Toxicol Appl Pharmacol, 195:309-320.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de octubre de 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Amer MR, et al. 2015. Safety of Popular Herbal Supplements in Lactating Women. J Hum Lact. 31(3):348-53.
- Ashar B H and Rowland-Seymour A. 2008, Advising Patients Who Use Dietary Supplements. Am J Med 121(2):91-7.
- Ciganda C and Laborde A. 2003, Herbal infusions used for induced abortion. J Toxicol Clin Toxicol 41(3):235-239.
- Dante G et al. 2013, Herb remedies during pregnancy: a systematic review of controlled clinical trials. J Maternal-Fetal and Neonatal Med 26(3): 306-312.
- Dante G et al. 2014, Herbal therapies in pregnancy: what works? Curr Opin Obstet Gynecol 26:83-91.
- Frawley J et al. 2015, Women's Use and Self-Prescription of Herbal Medicine during Pregnancy: An Examination of 1,835 Pregnant Women. Women's Health Issues 25-4, 396-402.
- Lei HL, et al. 2015. Relationship between risk factors for infertility in women and lead, cadmium, and arsenic blood levels: a cross-sectional study from Taiwan. BMC Public Health. 15:1220.
- Smeriglio A, et al. 2014, Herbal Products in Pregnancy: Experimental Studies and Clinical Reports. Phytother Res 28: 1107-1116.
- Trabace L, et al. 2015. "Natural" relief of pregnancy-related symptoms and neonatal outcomes: above all do no harm. J Ethnopharmacol. 174:396-402.
- Wang CC, et al. 2013, Pregnancy Outcomes, Embryonic and Fetal Development in Maternal Exposure to Chinese Medicines. Birth Defects Res (Part C) 99:275-291.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de octubre de 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Baard J, et al. 2020. The effect of beta-blockers on foetal birth weight in pregnancies in women with structural heart disease: a prospective cohort study. Cardiovasc J Afr 31(3):136-141.
- Bateman BT, et al. 2016. Late pregnancy β blocker exposure and risks of neonatal hypoglycemia and bradycardia. Pediatrics 138(3):e20160731.
- Davis RL, et al. 2011. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf 20(2):138-45.
- Firoz T, et al. 2014. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG 121(10):1210-8.
- Ruys TP,et al. 2014. Cardiac medication during pregnancy, data from the ROPAC. Int J Cardiol 177(1):124-8.
- Semczuk M. 1987. The effects of beta-adrenergic drugs on the human sperm motility in vitro. I. The effects of propranolol and isoprenaline. Andrologia. 19 Spec No:256-61.
- Tanaka K. 2016. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 80(10):2221-6.
- Wu Y. (2021). Risk of congenital malformations in offspring of women using β-blockers during early pregnancy: An updated meta-analysis of observational studies. Br J Clin Pharmacol 87(3):806-815.
- Xie RH, et al. 2014. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 175:124-8.
- Xie RH,et al. 2014. Beta-blockers increase the risk of being born small for gestational age or of being institutionalised during infancy. BJOG 121(9):1090-6.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de octubre de 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Aporta RR, et al. 1998. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica. 83:852-3.
- Amory, JK, et al. 2007. Miglustat has no apparent effect on spermatogenesis in normal men. Human Reproduction, ***22***(3), 702–707.
- Dornelles AD, et al. 2014. Breastfeeding in Gaucher disease: is enzyme replacement therapy safe? Clin Ther.36:990-1.
- Elstein Y, et al. 2004. Pregnancies in Gaucher disease: a 5-year study. Am J Obstet Gynecol. 190(2):435-41.
- Elstein D et al. 2014. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease. J Obstet Gynaecol Res.40(4):968-975.
- Gary, Sam E. et al. Recent Advances in the Diagnosis and Management of Gaucher Disease. Expert Review of Endocrinology & Metabolism. 13(2): 107–18
- Giannubilo SR, et al. 2015. Replacement therapy for Gaucher disease during pregnancy: A case report. J Reprod Infertil 16(1): 53-57.
- Granovsky-Grisaru, S et al. 2011. The management of pregnancy in Gaucher disease. Eur I Obstet Gynecol Reprod Biol. 156: (1) 3-8.
- Komninaka V, et al. 2020. Outcomes of pregnancies in patients with Gaucher Disease: The experience of a center of excellence on rare metabolic Disease-Gaucher Disease, in Greece. Eur J Obstet Gynecol Reprod Biol. 254:181-187.
- Korkmazer E, et al. 2015. Pregnancy and lactation in a patient with Gaucher disease receiving enzyme replacement therapy: Case report. Turkey J Clin Obstet Gynecol. 25:224-6.
- Lau H, et al. 2018. Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 68:226-231.
- Mamopoulos A M et al. 2009. Gaucher disease and pregnancy. J Obstet Gynaecol. 29: 240-242.
- Murphy E. 2015. Pregnancy in women with inherited metabolic disease. Obstet Med. 8(2): 61-67.
- Paskulin L, et al. Breastfeeding in patients with Gaucher disease: Is taliglucerase alfa safe? Molecular Genetics and Metabolism Reports, ***18***, 30–31.
- Rosenbaum H. 2015. Management of women with Gaucher disease in the reproductive age. Thromb Res. 135 Suppl 1:S49-51.
- Roy, A., et al. 2006. Shaping the sperm head: an ER enzyme leaves its mark. Journal of Clinical Investigation, 116(11), 2860–2863.
- Sekijima Y, et al. 2010. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of Imiglucerase in human breast milk. Clin Ther. 32(12): 2048-2052.
- Sherer Y, et al. 2002. Successful suc outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol. 81:161-3.
- Stirnemann J, et al. A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences, 18(2), 441.
- Weinreb, N. J. 2008. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opinion on Pharmacotherapy, 9(11), 1987–2000.
- Zimran A, et al. 2009. The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events. Blood Cells Mol Dis. 43:264-288.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de octubre de 2021.

Self-tanners, Tanning Pills, Tanning Booths

Selected References:

- Berle JO, et al. 2004. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome P450 genotypes. J Clin Psychiatry 65:1228-34. PMID: 15367050
- Brunel P, et al. 1994. [Follow-up of 151 pregnant women exposed to antidepressant treatment (MAOI excluded) during organogenesis.] Therapie 49:117-122.
- Eggermont E. 1973. Withdrawal symptoms in neonate associated with maternal imipramine therapy. Lancet 2:680.
- Misri S & Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 21(2):157-71.
- Mitchell JE and Popkin MK: Antidepressant drug therapy and sexual dysfunction in men: a review. J Clin Psychopharm 3:76-79, 1983.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 336:258-62.
- Overo KF, et al. 1997. Interaction of perphenazine with the kinetics of nortriptyline. Acta Pharmacol Toxicol; 40:97-105.
- Shearer WT, et al. 1972. Urinary retention in a neonate secondary to maternal ingestion of nortriptyline. J Pediatr 81:570-2.
- Schoretsanitis S, et al. 2020. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. Expert Opin Drug Metab Toxicol; 16(5):431-440.
- US Preventive Services Task Force, Curry SJ, et al. 2019. Interventions to Prevent Perinatal Depression: US Preventive Services Task Force Recommendation Statement. JAMA 321(6):580-587.
- Webster PA. 1973. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 2(7824):318-9.
- Weissman AM, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 161:1066-78. PMID: 15169695
- Wisner KL, et al. 2002. Postpartum depression. N Engl J Med. 347:194-9. PMID: 12124409.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de octubre de 2021.